CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.
Saved in:
| Title: | CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study. |
|---|---|
| Authors: | Ganzel C; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel., Frisch A; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel., Wolach O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Moshe Y; Department of Hematology and Bone Marrow Transplantation Unit, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel., Krayem B; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel., Dor N; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel., Broide E; Flow Cytometry Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel., Benayoun E; Flow Cytometry Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel., Rowe JM; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel., Ofran Y; Hematology and Bone Marrow Transplantation Department, the Eisenberg R&D Authority, Shaare Zedek Medical Center, and Faculty of Medicine, Hebrew University, Jerusalem, Israel. |
| Source: | British journal of haematology [Br J Haematol] 2025 Feb; Vol. 206 (2), pp. 551-555. Date of Electronic Publication: 2024 Dec 25. |
| Publication Type: | Journal Article; Clinical Trial |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
